Description

Science-led innovation and operations leader with experience translating complex research into product concepts, evidence plans, and commercial narratives across health-focused ventures. Track record building and governing cross-functional innovation roadmaps in lean environments, coordinating external partners, and producing decision-ready materials for executives, investors, and commercial stakeholders. Clinically trained (MPharm) with a strong validation mindset, comfortable bridging R&D, marketing, regulatory considerations, and customer-facing technical support.

Domaines d’expertise

Langues

Anglais
Bilingue ou natif
Allemand
Capacité professionnelle limitée

Préférences en matière de lieu de travail

Accepte de travailler sur site

Zurich (jusqu’à 50 km)

Perceptive Edge,
Founder & Advisor (Healthcare & Al Ventures)
janvier 2018 - Aujourd'hui (8 ans et 5 mois)
Zürich, Switzerland
• • ■ Advise early-stage health and science ventures on innovation strategy, portfolio focus, and translation of research into product concepts
• • and evidence plans.
• • Support academic and industry spin-outs with partner identification, collaboration setup, and governance rhythms to keep innovation
• • programs moving.
• • ■ Build decision frameworks that connect scientific rationale, validation milestones, and market activation requirements for commercial teams
• • and investors.
• • ■ Create concise, evidence-grounded narratives and materials that convert complex science into clear value propositions and responsible
• • claims. Current innovation projects
• • ■ PanGIA on positioning its non-invasive Al diagnostics platform for early cancer detection, shaping science-to-value messaging,
• • commercialization materials, and partnership/investor narratives around the PAS platform and urine-based liquid biopsy portfolio.
• • ■ Revealia on scientific positioning and go-to-market strategy for non-invasive women's health molecular diagnostics, including
• • evidence framing, partnership narratives, and regulatory-aware communications.
• • ■ (NDA-safe description): developing an early-stage wearable prototype focused on posture support, assessing
• • material and construction options to balance comfort, usability, and biomechanical effect.
Santersus AG,
Director, Business Development
janvier 2018 - janvier 2023 (5 ans)
Zürich, Switzerland
• • ■ Led company-level commercialization and partnership strategy in a science-driven startup environment, coordinating inputs across R&D,
• • analytics, regulatory considerations, and external stakeholders.
• • ■ Co-developed a cfDNA diagnostic innovation roadmap, aligning scientific rationale with validation milestones and downstream adoption
• • requirements.
• • ■ Built and managed external collaborations across Switzerland, Germany, and the UK; established clear deliverables and communication
• • cadence to maintain execution.
• • ■ Produced executive- and investor-ready materials translating technical results into decision points, positioning, and risk-managed claims
• • framing.
• • Supported fundraising progression through evidence and narrative development (Series A completed 2025).
Cannaray,
Scientific Advisor
janvier 2019 - décembre 2022 (3 ans et 11 mois)
London, UK
• • ■ Provided scientific and regulatory-pathway input to support responsible product positioning and stakeholder communications.
• • ■ Translated scientific concepts into accessible messaging for non-technical audiences, supporting customer and investor engagement.